Quest Diagnostics today said that it is now offering a molecular diagnostic test that can detect chromosome abnormalities associated with 85 developmental disorders affecting children.
 
The ClariSure is a microarray-based comparative genomic hybridization test that will be used to diagnose patients with mental retardation and Down syndrome among other disorders. Quest said it expects to provide physicians with test results within five days of receiving specimens at one of its facilities.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Chan Zuckerberg Initiative is investing in Cold Spring Harbor Laboratory's BioRxiv.

A study appearing in PLOS One finds that shortened consent forms don't affect clinical trial participants' understanding of the study.

The National Security Agency monitored signal intelligence for signs of "nefarious" genetic engineering projects, Gizmodo reports.

In Nature this week: barley genome sequenced, method for genotyping and phasing short tandem repeats, and more.